Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

ORIC Pharmaceuticals
240 E. Grand Ave., 2nd Floor
South San Francisco, CA 94080
Phone: 650-388-5600

ORIC Pharmaceuticals is a privately-held cancer therapy company focused on the discovery and development of small-molecule drugs that target treatment-resistant cancers, beginning with advanced prostate cancer. ORIC is leveraging its deep clinical understanding of the molecular mechanisms of cancer-treatment resistance, with its robust discovery platform, to develop new lines of therapies that will overcome resistance in cancer. The company brings together distinguished scientific founders, a leadership team and Board comprised of seasoned drug developers with proven track records, to solve the pervasive problem of resistance to cancer treatment. The company launched in 2014 and is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital and Kravis Investment Partners.

Key Contact
Name
Richard Heyman
Title
Interim CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
12/02/15 $53,000,000 Series B EcoR1 Capital
Foresite Capital
Kravis Investment Partners
OrbiMed Advisors
The Column Group
Topspin Partners
undisclosed